Work Here?
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$136.2M
Headquarters
Cambridge, Massachusetts
Founded
2019
Vizgen specializes in spatial genomics, focusing on high-resolution imaging to analyze biological samples at the cellular level. Its main product, MERSCOPE, utilizes MERFISH chemistry to collect detailed spatial data, which is especially beneficial for research in immuno-oncology, helping scientists understand tumor and immune interactions in various cancers. The MERSCOPE platform is complemented by a Gene Panel Design Portal, allowing researchers to create custom gene panels, and a cell segmentation tool called VPT, which accurately defines cell boundaries using MERFISH data. Unlike competitors, Vizgen's integrated approach combines advanced imaging with user-friendly tools for gene panel design and cell analysis. The company's goal is to enhance research capabilities in genomics and cancer biology by providing comprehensive tools and services to research institutions and laboratories.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$136.2M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Vizgen announces end of litigation with 10x Genomics and Harvard University.
Christian Uhrich, Investment Director at M Ventures, joins Vizgen Board of Directors; Chad Brown joins the company as Chief Commercial Officer
Vizgen launches Certified Service Provider (CSP) Program, expanding access to single-cell spatial genomics technology.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University. The U.S. District Court recently ruled in Vizgen’s favor, allowing Vizgen to expand its case based on new evidence uncovered during discovery in the litigation. The Court’s ruling substantially strengthens Vizgen’s position against 10x Genomics and Harvard, who must now defend against additional allegations of antitrust violations. Despite strenuous objections from 10x and Harvard, the Court approved Vizgen’s request to amend the claims to include additional antitrust allegations relating to 10x’s anticompetitive economic practices. These new allegations bolster Vizgen’s existing antitrust counterclaims against both 10x and Harvard, accusing them of conspiring to monopolize the market and obstructing Vizgen’s ability to compete globally
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced today the issuance by the US Patent Office of a patent that covers the in situ imaging of the spatial transcriptome. U.S. Patent No. 11,959,075 is for robust multiplex imaging of RNA and its spatial organization in a sample. "This latest patent relates to our MERFISH technology and enables groundbreaking advancements in the spatial genomics landscape," said Terry Lo, CEO, Vizgen, Inc. "It is another patent underscoring Vizgen’s leadership in the field, providing the industry’s best tools for single-cell spatial biology, and driving discoveries aimed at improving human health," he said
Find jobs on Simplify and start your career today
Discover companies similar to Vizgen
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$136.2M
Headquarters
Cambridge, Massachusetts
Founded
2019
Find jobs on Simplify and start your career today
Discover companies similar to Vizgen